Comparative Pharmacology
Head-to-head clinical analysis: CRESEMBA versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRESEMBA versus MYHIBBIN.
CRESEMBA vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isavuconazole, the active moiety of CRESEMBA, inhibits fungal cytochrome P450-dependent 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, disrupting fungal cell membrane synthesis and function.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
200 mg intravenously every 8 hours for the first 48 hours (6 doses), then 200 mg intravenously once daily; or 200 mg orally three times daily for the first 48 hours (6 doses), then 200 mg orally once daily.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) after oral administration, supporting once-daily dosing; steady-state achieved by Day 4-5.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Fecal: ~76% (primarily as unchanged drug); Renal: <1% (unchanged); Biliary: Not a major route; Metabolism via CYP3A4 to inactive metabolites eliminated fecally.
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category C
Category C
Antifungal
Antifungal